Research Analysts Set Expectations for Enanta Pharmaceuticals, Inc.’s Q3 2024 Earnings (NASDAQ:ENTA)

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) – Analysts at Leerink Partnrs dropped their Q3 2024 earnings per share estimates for shares of Enanta Pharmaceuticals in a research note issued to investors on Monday, May 6th. Leerink Partnrs analyst R. Ruiz now anticipates that the biotechnology company will post earnings of ($1.60) per share for the quarter, down from their previous estimate of ($1.46). The consensus estimate for Enanta Pharmaceuticals’ current full-year earnings is ($4.90) per share. Leerink Partnrs also issued estimates for Enanta Pharmaceuticals’ Q4 2024 earnings at ($1.38) EPS, FY2024 earnings at ($6.04) EPS, FY2025 earnings at ($4.70) EPS, FY2026 earnings at ($3.15) EPS and FY2027 earnings at ($1.55) EPS.

A number of other equities analysts have also weighed in on the company. JMP Securities lowered their target price on Enanta Pharmaceuticals from $23.00 to $22.00 and set a “market outperform” rating on the stock in a research note on Tuesday. StockNews.com upgraded Enanta Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Wednesday. JPMorgan Chase & Co. reduced their target price on shares of Enanta Pharmaceuticals from $12.00 to $11.00 and set an “underweight” rating for the company in a research report on Thursday, February 8th. Finally, HC Wainwright decreased their price target on shares of Enanta Pharmaceuticals from $28.00 to $27.00 and set a “buy” rating on the stock in a research note on Tuesday. One analyst has rated the stock with a sell rating, four have assigned a hold rating and two have assigned a buy rating to the company. According to MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $19.00.

Enanta Pharmaceuticals Stock Down 2.6 %

Enanta Pharmaceuticals stock opened at $12.76 on Thursday. The company’s 50-day moving average price is $14.88 and its two-hundred day moving average price is $12.08. The stock has a market cap of $269.95 million, a P/E ratio of -2.04 and a beta of 0.54. Enanta Pharmaceuticals has a twelve month low of $8.08 and a twelve month high of $28.25.

Enanta Pharmaceuticals (NASDAQ:ENTA) last announced its quarterly earnings results on Wednesday, February 7th. The biotechnology company reported ($1.58) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.18) by ($0.40). The business had revenue of $18.00 million for the quarter, compared to analyst estimates of $22.74 million. Enanta Pharmaceuticals had a negative net margin of 187.77% and a negative return on equity of 60.38%.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of ENTA. Nisa Investment Advisors LLC lifted its stake in Enanta Pharmaceuticals by 417.8% during the fourth quarter. Nisa Investment Advisors LLC now owns 2,827 shares of the biotechnology company’s stock worth $27,000 after purchasing an additional 2,281 shares during the last quarter. Clearstead Advisors LLC bought a new stake in shares of Enanta Pharmaceuticals during the 3rd quarter worth $57,000. Quantbot Technologies LP lifted its position in shares of Enanta Pharmaceuticals by 2,300.0% during the 3rd quarter. Quantbot Technologies LP now owns 7,200 shares of the biotechnology company’s stock worth $80,000 after buying an additional 6,900 shares during the last quarter. Sherbrooke Park Advisers LLC bought a new position in Enanta Pharmaceuticals in the third quarter valued at about $113,000. Finally, State Board of Administration of Florida Retirement System acquired a new position in Enanta Pharmaceuticals during the first quarter worth about $118,000. Institutional investors and hedge funds own 94.99% of the company’s stock.

About Enanta Pharmaceuticals

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.